Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

Impact · against what's priced in

Annexon (ANNX) presents several near-term binary catalysts, most notably a Q4 phase III readout for geographic atrophy and a European filing for GBS, which provide significant upside potential. The CEO's critical comments on the visual protection capabilities of Iveric (IVR) and Apellis (APLS) therapies introduce competitive tension but lack clinical data to fundamentally shift valuation.

ANNX+0.60

No priced-in read yet